Status:
UNKNOWN
The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy
Lead Sponsor:
Assiut University
Conditions:
Ectopic Pregnancy
Eligibility:
FEMALE
18-40 years
Phase:
NA
Brief Summary
The aim of this study is to : 1. Use of the aromatase inhibitor( letrozole) for the treatment of ectopic pregnancy compared to methotrexate. 2. Use of the Gnrh antagonist for the treatment of ectopic...
Eligibility Criteria
Inclusion
- Patients who have undisturbed ectopic pregnancy .Who are:
- have no significant pain
- have an unruptured tubal ectopic pregnancy with an adnexal mass smaller than 35mm with no visible heartbeat
- have a serum human chorionic gonadotropins level less than 1,500 IU/litre
- do not have an intrauterine pregnancy (as confirmed on an ultrasound scan) .
Exclusion
- An undisturbed ectopic pregnancy and significant pain
- An undisturbed ectopic pregnancy with an adnexal mass of 35 mm or larger
- An undisturbed ectopic pregnancy with a fetal heartbeat visible on an ultrasound scan
- An undisturbed ectopic pregnancy and a serum human chorionic gonadotropins level of 5,000 IU/litre or more
- intrauterine pregnancy
Key Trial Info
Start Date :
March 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04308343
Start Date
March 30 2020
End Date
September 1 2022
Last Update
March 16 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.